Category:Drug development

Subcategories

This category has the following 5 subcategories, out of 5 total.

Media in category "Drug development"

The following 39 files are in this category, out of 39 total.

• 
  2efnifostsaman.png 465 × 683; 13 KB
  
• A-Comprehensive-Panel-of-Three-Dimensional-Models-for-Studies-of-Prostate-Cancer-Growth-Invasion-pone.0010431.s013.ogv 1 min 6 s, 524 × 384; 8.71 MB
  
• 
  Aplaviroc development.svg 512 × 458; 23 KB
  
• 
  Asp-logo.svg 745 × 228; 25 KB
  
• 
  BrynjaSolmundsdottir.PNG 544 × 756; 20 KB
  
• 
  CEND-1 aka iRGD aka LSTA1 from SMILES.tif 3,230 × 3,091; 226 KB
  
• 
  Circuit d'un médicament.png 1,200 × 1,000; 76 KB
  
• 
  Development of lipid-lowering drugs.svg 1,420 × 460; 39 KB
  
• 
  DL20220923 drug dicovery design development.tif 4,571 × 2,776; 1.72 MB
  
• 
  DL20240219 clinical studies success rate.tif 3,780 × 600; 225 KB
  
• 
  Drug candidates for NAFLD and NASH by mechanism of action as of 2021.jpg 1,200 × 1,049; 79 KB
  
• 
  Drug Developing.png 2,048 × 670; 187 KB
  
• 
  Drug Evaluation Process.jpg 1,433 × 507; 76 KB
  
• Exploiting-Nanotechnologies-and-TRPV1-Channels-to-Investigate-the-Putative-Anandamide-Membrane-pone.0010239.s001.ogv 14 s, 640 × 640; 5.03 MB
  
• Exploiting-Nanotechnologies-and-TRPV1-Channels-to-Investigate-the-Putative-Anandamide-Membrane-pone.0010239.s002.ogv 17 s, 570 × 570; 2.28 MB
  
• Exploiting-Nanotechnologies-and-TRPV1-Channels-to-Investigate-the-Putative-Anandamide-Membrane-pone.0010239.s003.ogv 24 s, 640 × 640; 5.02 MB
  
• Exploiting-Nanotechnologies-and-TRPV1-Channels-to-Investigate-the-Putative-Anandamide-Membrane-pone.0010239.s004.ogv 12 s, 570 × 570; 3.01 MB
  
• 
  Imatinib development history.PNG 498 × 136; 4 KB
  
• 
  Imatinib development.svg 1,575 × 383; 12 KB
  
• 
  Imatinib in its binding site.svg 1,646 × 642; 73 KB
  
• 
  Interactive dose-response curve.gif 909 × 420; 237 KB
  
• 
  K1 HIV crab shape.jpg 722 × 564; 89 KB
  
• 
  K2 HIV 8-site-binding.tiff 3,300 × 2,550; 7.05 MB
  
• 
  K3 distorted key.jpg 1,987 × 1,929; 313 KB
  
• Methyl-Sulfone-Induces-Loss-of-Metastatic-Properties-and-Reemergence-of-Normal-Phenotypes-in-a-pone.0011788.s001.ogv 6.0 s, 312 × 240; 727 KB
  
• Methyl-Sulfone-Induces-Loss-of-Metastatic-Properties-and-Reemergence-of-Normal-Phenotypes-in-a-pone.0011788.s002.ogv 1.9 s, 312 × 240; 358 KB
  
• Modeling-Signal-Propagation-Mechanisms-and-Ligand-Based-Conformational-Dynamics-of-the-Hsp90-pcbi.1000323.s007.ogv 3.3 s, 640 × 480; 459 KB
  
• Modeling-Signal-Propagation-Mechanisms-and-Ligand-Based-Conformational-Dynamics-of-the-Hsp90-pcbi.1000323.s008.ogv 3.3 s, 640 × 480; 407 KB
  
• 
  New Tuberculosis (TB) Drugs Under Development (5102295729).jpg 497 × 405; 148 KB
  
• 
  Ponatinib development history.PNG 672 × 612; 19 KB
  
• 
  Ponatinib development.svg 1,557 × 1,555; 44 KB
  
• 
  Rivaroxaban SAr.svg 512 × 660; 10 KB
  
• Selective-Alpha-Particle-Mediated-Depletion-of-Tumor-Vasculature-with-Vascular-Normalization-pone.0000267.s004.ogv 5.0 s, 1,024 × 1,024; 7.26 MB
  
• 
  Substance 14 in its binding site.svg 741 × 350; 30 KB
  
• 
  The Pharmaceutical Development Process.png 1,030 × 722; 79 KB
  
• 
  Using genomic information to develop new flu vaccine.png 3,080 × 4,267; 315 KB
  
• 
  Using genomics to identify causes of drug resistance.png 1,155 × 838; 68 KB
  
• 
  Vicriviroc development.svg 512 × 958; 38 KB
  
• 
  Zebrafish light-dark test apparatus.tif 1,224 × 709; 299 KB